Christina Rostad

Assistant Professor

Emory University School of Medicine

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Christina Rostad is an Assistant Professor at Emory University School of Medicine in the United States. Her research focuses on vaccine immunogenicity and safety, particularly in relation to COVID-19, influenza, and respiratory syncytial virus (RSV). Recent publications include investigations into the antibody responses following mRNA vaccinations and clinical trials assessing vaccine effectiveness in diverse populations.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (15)

Rebecca Brady

Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES

Christina Rostad

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

The XBB.1.5 COVID-19 vaccine elicits a durable antibody response to ancestral and XBB.1.5 SARS-CoV-2 spike proteins

Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age

Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine

Clinical Progression Scale-Pediatrics: A Potential Metric of Respiratory Syncytial Virus Severity and Progression in Children

A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults

Prevalence, Clinical Severity, and Serotype Distribution of Pneumococcal Pneumonia Among Adults Hospitalized With Community-Acquired Pneumonia in Tennessee and Georgia, 2018-2022.

A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults

Development and comparison of immunologic assays to detect primary RSV infections in infants

Respiratory Coinfections in Children With SARS-CoV-2

Longitudinal Neutralizing and Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants Following Messenger RNA Coronavirus Disease 2019 Vaccination

Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.

Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults.

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.

An RSV live-attenuated vaccine candidate lacking G protein mucin domains is attenuated, immunogenic, and effective in preventing RSV in BALB/c mice.

A live single-cycle RSV vaccine expressing prefusion F protein.

Cat Scratch Disease: 9 Years of Experience at a Pediatric Center

Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults.

Addressing the global burden of paediatric critical COVID-19 and mortality

Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection.

Functional antibody responses to SARS-CoV-2 variants in children with COVID-19, MIS-C, and after two doses of BNT162b2 vaccination

Collaborators (15)

Rebecca Brady

Wilbur Chen

Sanjeev Kumar

Meagan Deming

Alberto Moreno

Serena Maria Dib

Thomas Martin

Michael Koval

Timothy A. Snider

Satoshi Kamidani

Christopher Stobart

Paul Goepfert

Gregory L Damhorst

Bo Liang

Evan Anderson

Make your next move.